| 영문 | family therapy | 한글 | 가족요법 |
|---|---|---|---|
| 설명 | 가족을 치료 대상으로 하는 심리요법 중의 하나. 가족중의 문제는 문제를 가진 개인만이 아니라 문제 가족을 대상으로 해결해 나갈 필요가 있다는 인식을 바탕으로 하여 가족 전체의 심리적 성숙을 목표로 한 요법이다. 크게 나누어 가족 중의 특정인을 대상으로 하여 각각 다른 독립된 치료를 하는 병행심리요법과 가족 전체를 동시 면접하는 방법을 주로 하는 합동가족요법이 있는데, 특히 후자를 가리켜 가족요법 이라고 하는 경우가 많다. |
||
| 영문 | intracavitary therapy | 한글 | 강내요법 |
|---|---|---|---|
| 설명 | 체강내, 즉 입안, 코안, 인두강, 식도, 곧창자, 질, 자궁목, 방광 등의 내강에, 때로는 병터에 의해 생긴 공동내에 방사선을 삽입해서 치료하는 것을 말한다. 주로 종양의 치료를 목적으로 한다. |
||
| 영문 | hyperbaric oxygenation therapy | 한글 | 고압산소요법 |
|---|---|---|---|
| 설명 | 대기압보다 높은 기압환경을 인공적으로 만들어 그 안에서 고농도의 산소를 흡입시키는 요법. 한국에서 연탄가스로 대표되는 일산화탄소의 급성중독의 치료에 많이 이용된 것으로, 보통 3대기압 정도로 가압된 고압산소실이나 고압산소탱크 속에 환자를 놓고 전신에 산소를 흡입시킨다. 고압실은 크고 작은 여러 가지가 있으며, 구조상 1실식-2실식-다실식이 있다. 가압 가스의 종류에는 산소-공기-혼합 가스등이 있고, 2~3 대기압 또는 그 이상의 고압 환경을 만든다. 임상적으로 응용범위가 넓어서 기계적 효과에 의하여 잠수부병이나 창자관마비에 의한 창자폐색 치료 등에 유효하고, 가스궤저 등의 무산소성 세균감염에서도 이용된다. 또 산소운반효과에 의하여 일산화탄소-심근경색-뇌색전증-출혈쇼크에 의한 급성의 조직산소결핍의 치료에 유효하다. 또 암의 방사선요법에 병용하면 이 요법으로 암세포의 분열이 왕성해져, 세포분열 중인 세포에 방사선을 조사함으로써 분열능력을 없애는 데 유효하여 고압산소흡입조사법이라고 한다. |
||
| 영문 | interstitial therapy | 한글 | 근접치료 |
|---|---|---|---|
| 설명 | 주로 종양의 치료를 목적으로 하여 인체 조직내에 방사선 물질을 삽입하여 방사선을 조사하는 치료법이다. Brachytherapy라고도 한다. |
||
| 영문 | symptomatic therapy | 한글 | 대증요법 |
|---|---|---|---|
| 설명 | 병의 원인을 찾아 없애기 곤란한 상황에서, 겉으로 나타난 병의 증상에 대응하여 처치를 하는 치료법. 열이 높을 때에 얼음주머니를 대거나 해열제를 써서 열을 내리게 하는 따위가 이에 속한다. |
||
| CT | calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ... |
|---|---|
| IT | immunological test; immunotherapy; implantation test; individual therapy; information technology; in... |
| MT | magnetization transfer; malaria therapy; malignant teratoma; mammary tumor; mammilothalamic tract; m... |
| ERT | esophageal radionuclide transit; estrogen replacement therapy; examination room terminal; external r... |
| GT | gait training; galactosyl transferase; gastrostomy; generation time; genetic therapy; gingiva treatm... |
| OR | Oestrogen receptor |
|---|---|
| CRRT | Continuous Renal Replacement Therapy |
| ERT | Enzyme replacement therapy |
| ERT | Estrogen Replacement Therapy |
| HRT | Hormonal Replacement Therapy |
| oestrogen replacement therapy | <endocrinology, gynaecology> The use of oestrogenic substances in postmenopausal or other oestrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, dyspareunia, and progressive development of osteoporosis. (12 Dec 1998) |
|---|
| renal replacement therapy | Procedures which temporarily or permanently remedy insufficient cleansing of body fluids by the kidneys. (12 Dec 1998) |
|---|---|
| replacement therapy | Therapy designed to compensate for a lack or deficiency arising from inadequate nutrition, from certain dysfunctions (e.g., glandular hyposecretion), or from losses (e.g., haemorrhage); replacement may be physiological or may entail administration of a substitute (e.g., a synthetic oestrogen in place of estradiol). (05 Mar 2000) |
| hormone replacement therapy | In females, treatment with sex hormones for a number for reasons, including menopause, partial or full hysterectomy, or amenorrhoea.In women, treatment with sex hormones is indicated for a number of reasons, including menopause, partial or full hysterectomy, or amenorrhoea. After menopause, conjugated oestrogens, estradiol, or estrone sulfate are given to reduce pain during intercourse, limit blood vessel effects, and prevent loss of bone mass. After radical hysterectomy, conjugated oestrogens are given for similar reasons. After menopause or partial hysterectomy, progestin is administered at the same time to offset an increased risk of endometrial cancer. In some amenorrhoeas, oestrogen is given to restore menses; if the therapy is unsuccessful, this may indicate the presence of pathology, for instance, pituitary tumour. Benefits for postmenopausal women include a lowered risk of heart attack (oestrogen lowers LDL and raises HDL levels), and prevention of osteoporosis, since the rate of bone loss is directly linked to a drop in oestrogen levels (see perimenopause). Medical opinion about the hazard posed by such therapy remains divided. Some studies have indicated increased incidence of breast cancer; however, a comprehensive 1992 review of the literature contradicted this finding. (05 Mar 2000) |
| enzyme replacement therapy | A type of medical treatment for patients who lack an important enzyme, the missing enzyme is injected into the patient. (09 Oct 1997) |
| catechol oestrogen | Any 2-hydroxylated derivative of an oestrogen; they, with their methylated derivatives, can account for up to one-half of all excreted oestrogen metabolites. (05 Mar 2000) |
| conjugated oestrogen | <pharmacology> An amorphous preparation of naturally occurring, water-soluble, conjugated forms of mixed oestrogen's obtained from the urine of pregnant mares; the principal oestrogen present is sodium estrone sulfate; suitable for parenteral, oral, and topical administration, and used in conditions responsive to oestrogen therapy. (05 Mar 2000) |
| selective oestrogen-receptor modulator | <pharmacology> An antioestrogen which possesses some, but not all, of the actions of oestrogen. For example, raloxifene (evista) is classified as a SERM because it prevents bone loss (like oestrogen) and lowers serum cholesterol (like oestrogen) but (unlike oestrogen) does not stimulate the endometrial lining of the uterus. Acronym: SERM (17 Jul 2002) |
| designer oestrogen | An engineered drug that possesses some, but not all, of the actions of oestrogen. Designer oestrogens are selective oestrogen-receptor modulators (SERMs). For example, raloxifene (trade name Evista) is classified as a SERM because it prevents bone loss (like oestrogen) and lowers serum cholesterol (like oestrogen) but (unlike oestrogen) does not stimulate the endometrial lining of the uterus. (12 Dec 1998) |
| oestrogen | <endocrinology, hormone> A generic term for oestrus producing steroid compounds, the female sex hormones. In humans, oestrogen is formed in the ovary, possibly the adrenal cortex, the testis and the foetoplacental unit, it has various functions in both sexes. It is responsible for the development of the female secondary sex characteristics and during the menstrual cycle it acts on the female genitalia to produce an environment suitable for the fertilization, implantation and nutrition of the early embryo. Oestrogen is used in oral contraceptives and as a palliative in cancer of the breast after menopause and cancer of the prostate, other uses include the relief of the discomforts of menopause, inhibition of lactation and treatment of osteoporosis, threatened abortion and various functional ovarian disorders. (18 Nov 1997) |
| oestrogen antagonist | <pharmacology> A drug or compound which inhibit or antagonise the action or biosynthesis of oestrogen. Tamoxifen also has agonist or stimulatory actions as well as blocking effects. There are also selective oestrogen-receptor modulators (SERMs). For example, raloxifene (trade name Evista) is classified as a SERM because it prevents bone loss (like oestrogen) and lowers serum cholesterol (like oestrogen) but (unlike oestrogen) does not stimulate the endometrial lining of the uterus. (12 May 2002) |
| oestrogen receptor | <cell biology> Cytoplasmic proteins that bind oestrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of oestrogen receptors in breast cancer patients has become clinically important and determines the likelihood of response to anti-oestrogen therapy with tamoxifen. (17 Jul 2002) |
| testosterone-oestrogen-binding globulin | A glycoprotein migrating as a beta-globulin. Its molecular weight, 52,000 or 95,000-115,000, indicates that it exists as a dimer. The protein binds testosterone, dihydrotestosterone, and estradiol in the plasma. Changes in its concentration significantly affect the ratio of unbound (biologically active) testosterone to estradiol in plasma. (12 Dec 1998) |
| acetate replacement factor | <biochemistry> 1,2 dithiolane 3 valeric acid. Regarded as a coenzyme in the oxoglutarate dehydrogenase complex of the citric acid cycle. Involved generally in oxidative decarboxylations of _ keto acids. A growth factor for some organisms. (18 Nov 1997) |
| arthroplasty, replacement | Partial or total replacement of a joint. (12 Dec 1998) |
| arthroplasty, replacement, hip | Replacement of the hip joint. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|